Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide.

Michael E Franks1, Gordon R Macpherson, William D Figg

  • 1Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20030, USA.

Lancet (London, England)
|June 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Blood·2020
Same author

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

The New England journal of medicine·2020
Same author

Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.

International journal of nanomedicine·2020
Same author

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)<sub>n</sub> Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

International journal of molecular sciences·2020
Same author

Stem cell clinics: risk of proliferation.

The Lancet. Oncology·2020
Same author

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

Journal of pharmaceutical and biomedical analysis·2020
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Thalidomide, once a human teratogen, is now a promising treatment for cancer and inflammatory diseases. Understanding its molecular pharmacology is key to its safe and effective clinical application.

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Background:

  • Thalidomide's history as a human teratogen necessitates careful consideration in drug development.
  • Past misuse highlights the importance of understanding a drug's molecular pharmacology and toxicities.
  • Recent clinical applications demonstrate thalidomide's evolving therapeutic potential.

Purpose of the Study:

  • To summarize thalidomide's applications, focusing on clinical trials from the past decade.
  • To correlate molecular pharmacology with clinical trial data for a mechanism-guided understanding.
  • To provide insights into thalidomide's activity in treating cancer and inflammatory diseases.

Main Methods:

  • Review of clinical trials published within the last 10 years.

Related Experiment Videos

  • Analysis of existing literature on thalidomide's molecular pharmacology.
  • Integration of clinical data with pharmacological knowledge.

    • Main Results:

    • Thalidomide demonstrates efficacy in treating various cancers and inflammatory conditions.
    • Clinical outcomes are being increasingly understood through the lens of molecular mechanisms.
    • Ongoing research continues to refine thalidomide's therapeutic index.

    Conclusions:

    • Thalidomide's dual nature as a teratogen and therapeutic agent requires a deep understanding of its pharmacology.
    • Mechanism-guided approaches are crucial for optimizing thalidomide's use in clinical practice.
    • Continued research into thalidomide's molecular pharmacology will enhance its application in oncology and immunology.